Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1541-1560 of 1,738 trials

Idiopathic Pulmonary Fibrosis: CAL101 Treatment Study

We are studying whether CAL101 can improve lung function in patients with idiopathic pulmonary fibrosis compared to a placebo. The trial also looks at the safety of this new treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Esophageal Cancer: Tislelizumab for Elderly Patients

We are studying Tislelizumab to see if it helps elderly patients with advanced esophageal cancer who cannot receive chemotherapy. The trial aims to assess survival rates and quality of life improvements.

Esophageal Squamous Cell Carcinoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: L-Annamycin with Cytarabine

We are studying a new treatment combining L-Annamycin with Cytarabine for adults with difficult-to-treat acute myeloid leukemia. The goal is to see if this combination can help achieve remission better than a placebo.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Chronic Inflammatory Demyelinating Polyneuropathy: Batoclimab Study

We are studying the long-term safety and tolerability of batoclimab in adults with CIDP. This trial aims to see how well the medication works for managing symptoms over time.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Idiopathic Membranous Nephropathy: AP1189 Study

We are exploring whether the medication AP1189 can improve kidney function and reduce protein in urine for patients with idiopathic membranous nephropathy. This study involves patients already receiving ACE inhibitors or angiotensin II receptor blockers.

Membranous Nephropathy1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Ketamine for Treating Disorders of Consciousness After Coma

We are studying whether intravenous ketamine can help patients regain consciousness after a coma. The trial also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyPsychiatry

STOP-LEUKEMIA: Metformin for Blood Disorders

We are investigating whether metformin can help prevent leukemia in patients with clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes. This study will assess the safety of metformin and explore how it may affect disease progression.

Myelodysplastic Syndromes (MDS)Clonal Cytopenia of Undetermined Significance (CCUS)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Heart Failure: PF-07328948 Study

We are testing a new oral medication for adults with heart failure to see if it improves heart function and symptoms compared to a placebo. The study also examines the safety of this treatment.

Heart Failure6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Cerebral Palsy: IncobotulinumtoxinA Treatment

We are studying the safety and effectiveness of IncobotulinumtoxinA for children with upper and lower limb spasticity due to cerebral palsy. This trial includes both new and previously treated patients to see how well the treatment works.

Muscle Spasticity1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyPediatrics

CBD for Alcohol Use Disorder: A Phase II Trial

We are studying whether adding cannabidiol to standard treatment helps patients with severe alcohol use disorder stay abstinent after inpatient care. The trial also looks at the safety of CBD and its effects on withdrawal and anxiety symptoms.

Alcohol Use Disorder≤3 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesInternal MedicinePsychiatry

Chronic Kidney Disease: Vicadrostat and Empagliflozin Study

We are investigating whether starting vicadrostat with empagliflozin helps people with chronic kidney disease. The study compares two different ways of starting the medications to see which is more effective.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteDiabetologyNephrology

Usher Syndrome Type 1B: AAVB-081 Injection Study

We are testing a new subretinal injection for patients with Usher Syndrome Type 1B to see if it is safe and how it affects retinal health. The goal is to find a dose that balances safety and effectiveness.

Usher Syndrome Type 1B>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Immune Thrombocytopenia: Pirtobrutinib Study

We are investigating a new medication, pirtobrutinib, for adults with immune thrombocytopenia. The study aims to assess its safety and effectiveness compared to a placebo.

Immune Thrombocytopenia≤3 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteHematology

Ischemic Stroke: Thrombolytic Therapy with rtPA

We are studying a new treatment for patients with acute ischemic stroke who are on blood thinners. The goal is to see if this therapy improves recovery compared to a placebo after reversing the blood thinner's effects.

Ischaemic Stroke3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Colorectal Cancer: Intravenous Iron Infusion Study

We are investigating whether intravenous iron can improve physical capacity and immune response in non-anemic patients with colorectal cancer. This study compares the effects of iron to a placebo to understand its potential benefits.

Iron Deficiency>2 yearsEfficacy phase (II)Investigational MedicinesGastroenterologyOncology

Allergic Rhinitis: New Immunotherapy Treatment

We are studying a new subcutaneous immunotherapy for patients with allergic rhinitis or rhinoconjunctivitis, with or without asthma. The goal is to evaluate its safety and effectiveness compared to a placebo.

Moderate to Severe Allergic Rhinitis with or without Asthma1-2 yearsEfficacy phase (II)Standard MedicinesAllergologyInternal Medicine

Myoclonic Astatic Epilepsy: Fenfluramine Safety Study

We are monitoring the long-term safety of Fenfluramine as an add-on therapy for patients with Myoclonic Astatic Epilepsy. This study aims to ensure the treatment is safe and effective for managing seizures.

Myoclonic-Astatic Epilepsy>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Early Alzheimer’s Disease: AD04 Treatment Study

We are testing a new treatment called AD04 to see if it can slow the progression of early Alzheimer’s disease. The study will also evaluate the safety of AD04 and its effects on quality of life.

Early Alzheimer's Disease>2 yearsEfficacy phase (II)Investigational MedicinesNeurologyPsychiatry

Diabetic Foot Syndrome: Stem Cell Treatment Study

We are investigating whether a new therapy using stem cells can help heal chronic wounds in people with diabetic foot syndrome. The study will compare this treatment to standard care to assess its safety and effectiveness.

Diabetic Foot Ulcer1-2 yearsEfficacy phase (II)Investigational MedicinesDiabetologyInternal Medicine

Metastatic Colorectal Cancer: Cetuximab Treatment Study

We are exploring a new treatment approach using cetuximab for patients with specific genetic markers in metastatic colorectal cancer. The study aims to understand its effectiveness, safety, and impact on quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology